Search research articles
Contact Us
Filters
Showing results (1-10 of 4,689) with videos related to
Page
of 469
Sort By:
Therapeutic Drug Monitoring
|
January 1, 1985
Interference with high performance liquid chromatographic chloramphenicol assay in a patient receiving dobutamine
M B Powel, C A Robinson, R L Furner
Therapeutic Drug Monitoring
|
January 1, 1985
Fallacious results from measuring salivary carbamazepine concentrations
R G Dickinson, W D Hooper, A R King, et al.
Therapeutic Drug Monitoring
|
September 21, 2022
Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation
Michael Oellerich, Klemens Budde, Bilgin Osmanodja, et al.
Therapeutic Drug Monitoring
|
January 1, 1986
Plasma nor1-chlorpromazine concentrations: effects of age, race, and sex
R C Young
Therapeutic Drug Monitoring
|
January 1, 1986
Factors influencing theophylline disposition in 179 newborns
J T Gilman, P Gal, R S Levine, et al.
Therapeutic Drug Monitoring
|
January 1, 1986
Simultaneous measurement of bupivacaine, etidocaine, lidocaine, meperidine, mepivacaine, and methadone
D E Coyle, D D Denson
Therapeutic Drug Monitoring
|
January 1, 1979
Comparison of three assay procedures for theophylline determination
I S Kampa, L K Dunikoski, J I Jarzabek, et al.
Therapeutic Drug Monitoring
|
October 17, 2022
Impact of ABCC2 1249G>A and -24C>T Polymorphisms on Lacosamide Efficacy and Plasma Concentrations in Uygur Pediatric Patients With Epilepsy in China
Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, et al.
Therapeutic Drug Monitoring
|
December 20, 2014
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
Thomas Van Stappen, Els Brouwers, Sophie Tops, et al.
Therapeutic Drug Monitoring
|
November 11, 2014
Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation
Ozgur Yorbik, Caner Mutlu, Selma Ozilhan, et al.
Page
of 469
Search research articles
Search
Showing results (1-10 of 4,689) with videos related to
Sort By:
Page
of 469
Therapeutic Drug Monitoring
|
January 1, 1985
Interference with high performance liquid chromatographic chloramphenicol assay in a patient receiving dobutamine
M B Powel, C A Robinson, R L Furner
Therapeutic Drug Monitoring
|
January 1, 1985
Fallacious results from measuring salivary carbamazepine concentrations
R G Dickinson, W D Hooper, A R King, et al.
Therapeutic Drug Monitoring
|
September 21, 2022
Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation
Michael Oellerich, Klemens Budde, Bilgin Osmanodja, et al.
Therapeutic Drug Monitoring
|
January 1, 1986
Plasma nor1-chlorpromazine concentrations: effects of age, race, and sex
R C Young
Therapeutic Drug Monitoring
|
January 1, 1986
Factors influencing theophylline disposition in 179 newborns
J T Gilman, P Gal, R S Levine, et al.
Therapeutic Drug Monitoring
|
January 1, 1986
Simultaneous measurement of bupivacaine, etidocaine, lidocaine, meperidine, mepivacaine, and methadone
D E Coyle, D D Denson
Therapeutic Drug Monitoring
|
January 1, 1979
Comparison of three assay procedures for theophylline determination
I S Kampa, L K Dunikoski, J I Jarzabek, et al.
Therapeutic Drug Monitoring
|
October 17, 2022
Impact of ABCC2 1249G>A and -24C>T Polymorphisms on Lacosamide Efficacy and Plasma Concentrations in Uygur Pediatric Patients With Epilepsy in China
Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, et al.
Therapeutic Drug Monitoring
|
December 20, 2014
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
Thomas Van Stappen, Els Brouwers, Sophie Tops, et al.
Therapeutic Drug Monitoring
|
November 11, 2014
Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation
Ozgur Yorbik, Caner Mutlu, Selma Ozilhan, et al.
Page
of 469